Clinical Trial

Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase Ib, randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Efsubaglutide Alfa Injection following multiple-dose administration in Chinese adolescent participants with obesity.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-31
Trial Details
NCT Number NCT07693426
Lead Sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Conditions Adolescence Obesity
Enrollment 36 participants
Start Date 2026-07-16
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30